Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMN with Radioimmunotherapy in Advanced NSCLC
NCT06966583Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nicotinamide mononucleotide in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Primary endpoint: Number of Participants With Adverse Events and/or Dose Limiting Toxicities up to 24 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
nicotinamide mononucleotide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06966583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966583.